IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma()

The insulin-like growth factor 1 receptor (IGF-1R) has surfaced as a significant target in multiple solid cancers due to its fundamental roles in pro-survival and anti-apoptotic signaling. However, development of resistance to IGF-1R blockade represents a significant hindrance and limits treatment e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xiaolin, Yeung, Choh, Heske, Christine, Mendoza, Arnulfo, Helman, Lee J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415145/
https://www.ncbi.nlm.nih.gov/pubmed/25925378
http://dx.doi.org/10.1016/j.neo.2015.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415145/
https://www.ncbi.nlm.nih.gov/pubmed/25925378
http://dx.doi.org/10.1016/j.neo.2015.03.001

Ejemplares similares